Blood-pool imaging using technetium-99m-labeled liposomes

Beth Goins, William T Phillips, Robert Klipper

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

This study evaluated two 99mTc-liposome formulations as potential blood-pool agents in comparison with standard 99mTc-red cells and 99mTc-human serum albumin (HSA). Methods: Liposomes with no surface modification or coated with polyethylene glycol (PEG) were labeled with 99mTc using the lipophilic chelator, HMPAO. Autologous red cells were labeled with 99mTc using in vitro or in vive techniques. Technetium-99m- HSA was supplied commercially. Rabbits were injected intravenously with 99mTc-liposomes, 99mTc-red cells or 99mTc-HSA. Static images were acquired and blood samples collected. Results: Technetium-99m-liposome images showed prominent blood-pool activity compared to lung and liver activities, which were similar to those acquired for 99mTc-red cells, but better than 99mTc-HSA. Heart-to-lung ratios were not significantly different between 99mTc-liposome formulations or for either formulation compared to 99mTc-red cells. The ratios were higher, however, than for 99mTc-HSA. Heart-to-liver ratios were higher for PEG 99mTc-liposomes than they were for neutral 99mTc-liposomes and 99mTc-HSA, but were not significantly different than 99mTc-red cells. Bladder activities for both 99mTc- liposome formulations were 3-6 times lower than for the other agents. PEG 99mTc-liposomes remained in circulation 1.6 times longer than any of the other agents. Conclusions: Technetium-99m-liposomes, independent of surface modification, had excellent circulation persistence and in vivo stability when compared to 99mTc-red cells and 99mTc-HSA. PEG 999mTc- liposomes performed better than neutral 99mTc-liposomes due to lower liver background activity. Advantages of PEG 99mTc-liposomes compared to 99mTc-red cells include: (a) only one venipuncture, (b) little exposure to patient's blood, (c) excellent in vitro and in vivo stability and (d) lack of drug interference.

Original languageEnglish (US)
Pages (from-to)1374-1379
Number of pages6
JournalJournal of Nuclear Medicine
Volume37
Issue number8
StatePublished - Aug 1996

Fingerprint

Technetium
Liposomes
Technetium Tc 99m Aggregated Albumin
Liver
Lung
Phlebotomy
Chelating Agents
Serum Albumin
Urinary Bladder

Keywords

  • blood-pool imaging
  • liposomes
  • polyethylene glycol
  • technetium-99m- HMPAO
  • technetium-99m-liposomes
  • ventriculography

ASJC Scopus subject areas

  • Radiological and Ultrasound Technology

Cite this

Goins, B., Phillips, W. T., & Klipper, R. (1996). Blood-pool imaging using technetium-99m-labeled liposomes. Journal of Nuclear Medicine, 37(8), 1374-1379.

Blood-pool imaging using technetium-99m-labeled liposomes. / Goins, Beth; Phillips, William T; Klipper, Robert.

In: Journal of Nuclear Medicine, Vol. 37, No. 8, 08.1996, p. 1374-1379.

Research output: Contribution to journalArticle

Goins, B, Phillips, WT & Klipper, R 1996, 'Blood-pool imaging using technetium-99m-labeled liposomes', Journal of Nuclear Medicine, vol. 37, no. 8, pp. 1374-1379.
Goins B, Phillips WT, Klipper R. Blood-pool imaging using technetium-99m-labeled liposomes. Journal of Nuclear Medicine. 1996 Aug;37(8):1374-1379.
Goins, Beth ; Phillips, William T ; Klipper, Robert. / Blood-pool imaging using technetium-99m-labeled liposomes. In: Journal of Nuclear Medicine. 1996 ; Vol. 37, No. 8. pp. 1374-1379.
@article{315319ca06a84e459d3a812d33574ebc,
title = "Blood-pool imaging using technetium-99m-labeled liposomes",
abstract = "This study evaluated two 99mTc-liposome formulations as potential blood-pool agents in comparison with standard 99mTc-red cells and 99mTc-human serum albumin (HSA). Methods: Liposomes with no surface modification or coated with polyethylene glycol (PEG) were labeled with 99mTc using the lipophilic chelator, HMPAO. Autologous red cells were labeled with 99mTc using in vitro or in vive techniques. Technetium-99m- HSA was supplied commercially. Rabbits were injected intravenously with 99mTc-liposomes, 99mTc-red cells or 99mTc-HSA. Static images were acquired and blood samples collected. Results: Technetium-99m-liposome images showed prominent blood-pool activity compared to lung and liver activities, which were similar to those acquired for 99mTc-red cells, but better than 99mTc-HSA. Heart-to-lung ratios were not significantly different between 99mTc-liposome formulations or for either formulation compared to 99mTc-red cells. The ratios were higher, however, than for 99mTc-HSA. Heart-to-liver ratios were higher for PEG 99mTc-liposomes than they were for neutral 99mTc-liposomes and 99mTc-HSA, but were not significantly different than 99mTc-red cells. Bladder activities for both 99mTc- liposome formulations were 3-6 times lower than for the other agents. PEG 99mTc-liposomes remained in circulation 1.6 times longer than any of the other agents. Conclusions: Technetium-99m-liposomes, independent of surface modification, had excellent circulation persistence and in vivo stability when compared to 99mTc-red cells and 99mTc-HSA. PEG 999mTc- liposomes performed better than neutral 99mTc-liposomes due to lower liver background activity. Advantages of PEG 99mTc-liposomes compared to 99mTc-red cells include: (a) only one venipuncture, (b) little exposure to patient's blood, (c) excellent in vitro and in vivo stability and (d) lack of drug interference.",
keywords = "blood-pool imaging, liposomes, polyethylene glycol, technetium-99m- HMPAO, technetium-99m-liposomes, ventriculography",
author = "Beth Goins and Phillips, {William T} and Robert Klipper",
year = "1996",
month = "8",
language = "English (US)",
volume = "37",
pages = "1374--1379",
journal = "Journal of Nuclear Medicine",
issn = "0161-5505",
publisher = "Society of Nuclear Medicine Inc.",
number = "8",

}

TY - JOUR

T1 - Blood-pool imaging using technetium-99m-labeled liposomes

AU - Goins, Beth

AU - Phillips, William T

AU - Klipper, Robert

PY - 1996/8

Y1 - 1996/8

N2 - This study evaluated two 99mTc-liposome formulations as potential blood-pool agents in comparison with standard 99mTc-red cells and 99mTc-human serum albumin (HSA). Methods: Liposomes with no surface modification or coated with polyethylene glycol (PEG) were labeled with 99mTc using the lipophilic chelator, HMPAO. Autologous red cells were labeled with 99mTc using in vitro or in vive techniques. Technetium-99m- HSA was supplied commercially. Rabbits were injected intravenously with 99mTc-liposomes, 99mTc-red cells or 99mTc-HSA. Static images were acquired and blood samples collected. Results: Technetium-99m-liposome images showed prominent blood-pool activity compared to lung and liver activities, which were similar to those acquired for 99mTc-red cells, but better than 99mTc-HSA. Heart-to-lung ratios were not significantly different between 99mTc-liposome formulations or for either formulation compared to 99mTc-red cells. The ratios were higher, however, than for 99mTc-HSA. Heart-to-liver ratios were higher for PEG 99mTc-liposomes than they were for neutral 99mTc-liposomes and 99mTc-HSA, but were not significantly different than 99mTc-red cells. Bladder activities for both 99mTc- liposome formulations were 3-6 times lower than for the other agents. PEG 99mTc-liposomes remained in circulation 1.6 times longer than any of the other agents. Conclusions: Technetium-99m-liposomes, independent of surface modification, had excellent circulation persistence and in vivo stability when compared to 99mTc-red cells and 99mTc-HSA. PEG 999mTc- liposomes performed better than neutral 99mTc-liposomes due to lower liver background activity. Advantages of PEG 99mTc-liposomes compared to 99mTc-red cells include: (a) only one venipuncture, (b) little exposure to patient's blood, (c) excellent in vitro and in vivo stability and (d) lack of drug interference.

AB - This study evaluated two 99mTc-liposome formulations as potential blood-pool agents in comparison with standard 99mTc-red cells and 99mTc-human serum albumin (HSA). Methods: Liposomes with no surface modification or coated with polyethylene glycol (PEG) were labeled with 99mTc using the lipophilic chelator, HMPAO. Autologous red cells were labeled with 99mTc using in vitro or in vive techniques. Technetium-99m- HSA was supplied commercially. Rabbits were injected intravenously with 99mTc-liposomes, 99mTc-red cells or 99mTc-HSA. Static images were acquired and blood samples collected. Results: Technetium-99m-liposome images showed prominent blood-pool activity compared to lung and liver activities, which were similar to those acquired for 99mTc-red cells, but better than 99mTc-HSA. Heart-to-lung ratios were not significantly different between 99mTc-liposome formulations or for either formulation compared to 99mTc-red cells. The ratios were higher, however, than for 99mTc-HSA. Heart-to-liver ratios were higher for PEG 99mTc-liposomes than they were for neutral 99mTc-liposomes and 99mTc-HSA, but were not significantly different than 99mTc-red cells. Bladder activities for both 99mTc- liposome formulations were 3-6 times lower than for the other agents. PEG 99mTc-liposomes remained in circulation 1.6 times longer than any of the other agents. Conclusions: Technetium-99m-liposomes, independent of surface modification, had excellent circulation persistence and in vivo stability when compared to 99mTc-red cells and 99mTc-HSA. PEG 999mTc- liposomes performed better than neutral 99mTc-liposomes due to lower liver background activity. Advantages of PEG 99mTc-liposomes compared to 99mTc-red cells include: (a) only one venipuncture, (b) little exposure to patient's blood, (c) excellent in vitro and in vivo stability and (d) lack of drug interference.

KW - blood-pool imaging

KW - liposomes

KW - polyethylene glycol

KW - technetium-99m- HMPAO

KW - technetium-99m-liposomes

KW - ventriculography

UR - http://www.scopus.com/inward/record.url?scp=0029778094&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029778094&partnerID=8YFLogxK

M3 - Article

C2 - 8708778

AN - SCOPUS:0029778094

VL - 37

SP - 1374

EP - 1379

JO - Journal of Nuclear Medicine

JF - Journal of Nuclear Medicine

SN - 0161-5505

IS - 8

ER -